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ABSTRACT
Objectives: The study aims to determine the incidence of secondary hyperparathyroidism (SHPT) in chronic kidney disease patients, the correlation 
between creatinine, parathyroid hormone (PTH) and phosphate, and calcium in renal disease.
Methods: A retrospective cross-sectional study was performed, a total of 100 hemodialysis patients’ reports were analyzed from January 2019 to 
December 2019, at Hebron Governmental Hospital, in Hebron, Palestine. The patients’ data were collected, including creatinine level, calcium, and 
phosphorus in addition to PTH concentrations. Twenty-five healthy persons with normal kidney function were also included in the study as a control 
for comparison. Statistical Package for the Social Sciences version 22 was used to analyze the data. T-test and Pearson’s tests were used to study the 
results. R (Pearson’s test) was used to determine the correlation between creatinine, PTH, phosphate, and calcium.
Results: The mean values of serum of creatinine, phosphate, calcium, and PTH were determined for both patients and the control. Levels of PTH 
were significantly higher in kidney failure patients and positively correlated with creatinine and phosphate. However, levels of PTH were significantly 
negatively correlated with calcium. All patients included in the study have very high levels of PTH PTH. This increase might be due to many factors that 
contributed to the hypersecretion of PTH. The correlations between these predisposing factors of SHPT are explained.
Conclusion: The study showed that SHPT is common among patients with end-stage renal disease. The most complications of SHPT are mineral and 
bone metabolism disorders and cardiovascular diseases. Thus, early detection and treatment of SHPT may control these complications.
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INTRODUCTION
There is a relationship between kidney failure and secondary 
hyperparathyroidism (SHPT) which should be considered to 
prevent any consequences such as mineral and bone metabolism 
disorders and cardiovascular diseases. SHPT is known to be one of 
the complications of kidney failure. Usually, patients that start from 
stage three of kidney failure, their glomerular filtration rate (GFR) 
is less than 60 (mL/min/1.73 m2) [1]. This causes an imbalance of 
Vitamin D, calcium, parathyroid hormone (PTH), phosphorus, and 
fibroblast growth factor 23 (FGF 23) concentrations in the blood [2]. 
In the context of the pathophysiology of kidney failure, there is a 
decrease in the concentration of Vitamin D due to a reduction in the 
production of the 25-Hydroxyvitamin D3 1-alpha-hydroxylase (VD3 
1A hydroxylase) enzyme that converts 25-hydroxy Vitamin D to 
1,25-dihydroxy Vitamin D3 (1,25(OH)2D) [3]. This effect decreases the 
absorption of calcium and causes hypocalcemia. However, this situation 
can activate the parathyroid gland and enhances the secretion of PTH; 
as a compensation effect for a deficiency of calcium in the body. The 
improper nephron function may cause a decrease in the excretion of 
phosphorus in the urine and increases the reabsorption to the blood, 
leading to hyperphosphatemia. Besides, this situation increases the 
concentration of FGF, which further decreases 1,25(OH)2D levels by 
decreasing the expression of VD3 1A hydroxylase. FGF-23 acts directly 
on the parathyroid gland and suppresses PTH secretion through the 
FGFR-1-Klotho complex [4]. On the other hand, other factors can cause 
hyperparathyroidism, including a reduction of expression of Vitamin D 
receptors, calcium-sensing receptors, and FGF-23 receptors in the 
parathyroid glands [5]. At this stage, hyperphosphatemia decreases 
1,25(OH)2D and calcium (hypocalcemia), these all contribute to 
increasing PTH messenger ribonucleic acid levels and PTH synthesis. 
These changes can cause many complications, for example, stimulating 
osteoclast activity which, in turn, leads to a high turnover of bone 
disease and fragility fractures. These complications were 2–4 times 
more frequent in patients with SHP compared with normal individuals. 
However, SHP may play a causal role in the development of vascular 
calcifications, ischemic cardiovascular events, and cardiac failure. 
This research aimed to determine the relationship between renal 
failure and hyperparathyroidism by measuring the levels of creatinine, 
phosphorus, calcium, and PTH in patients with kidney failure.
METHODS
The consent of the Palestinian Ministry of Health (MOH) was obtained 
for this study, which was conducted during the period from 27 February 
2020 to 07 March 2020. However, a retrospective study was performed, 
and data were collected from the information system unit in Hebron 
Governmental Hospital. A total of 100 reports of hemodialysis patients 
from the year 2019 were included in the study. Twenty-five healthy 
people with normal kidney function were included as a control. The 
control group met the inclusion criteria, which includes normal kidney 
function and normal kidney profile. The clinical biochemistry profile of 
PTH, calcium, creatinine, and phosphate was checked for both patients 
and control. The Statistical Package for the Social Sciences version 22 
software was used to analyze the data. A t-test was used to check the 
differences between patients and normal control results. R (Pearson’s 
test) was used to determine the correlation between phosphate, calcium, 
creatinine, and PTH. The significant result was determined at p<0.05.
RESULTS
One hundred end-stage renal disease (ESRD) patients’ data were 
collected and statistically analyzed. Their data indicate that there 
are associations between different elements (creatinine, phosphate, 
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calcium, and PTH). The mean value of serum creatinine was found 
to be (10±3.02 mg/dL), while for phosphate, calcium, and PTH were 
(6.03±1.13 mg/dL), (7.59±0.93 mg/dL), and (975.1±408 mg/dL), 
respectively. Twenty-five healthy persons with normal kidney functions 
were also statistically analyzed as normal control and their data were 
compared with kidney failure patients. The mean value of calcium 
was found to be (8.9±05 mg/dL) for the control, while their data 
for phosphate and PTH were found to be (4.14±0.61 mg/dL) and 
(53.96±12.7 mg/dL), respectively, as shown in Figs. 1 and 2. It was found 
that 32% (32 patients) had a normal level of serum calcium compared 
to the normal range which is (8.5–10.2 mg/dL), while 68% (68 patients) 
found to have serum calcium less than 8.5 mg/dL, as shown in Fig. 3. 
A Scatter plot shows that PTH has a significant negative correlation 
with calcium (p<0.05) (Fig. 4). Results show that there is a significant 
negative correlation between phosphate and calcium (p<0.05), as 
shown in Fig. 5. Data show that 28 patients (28%) had a normal level of 
serum phosphate, 2% (two patients) had a phosphate <3.5 mg/dL, and 
most patients (70 patients) had a high level of phosphate compare to 
the normal range which is (3.5–5.5 mg/dL). The 70 patients who have 
a high level of phosphate, their serum phosphate was above 5.5 mg/
dL, as shown in Fig. 6. However, the phosphorus level has a significant 
positive correlation with creatinine in this study (p<0.005), as indicated 
in Fig. 7. A Scatter plot also shows that PTH has a significant positive 
correlation between phosphate and creatinine (Figs. 8, and 9).
DISCUSSION
SHPT is one of the most common complications among ESRD patients 
that should be controlled to prevent other complications such as bone 
and mineral metabolism disorders and cardiovascular diseases. When the 
mean value of the control is compared to the mean value of patients, we 
have noticed that there are a significant difference in all parameters, as the 
mean values of phosphate and parathyroid were higher for kidney failure 
patients (Figs. 1 and 2), whereas the mean value of calcium (Fig. 1) was 
higher for control. These results confirmed that there are relationships 
between these parameters and SHPT as mentioned previously.
In this research study, it was found that all the patients had very high levels 
of PTH. The high level might be due to various factors that contributed to 
the hypersecretion of PTH. The correlation between these predisposing 
factors of SHPT is explained. Fig. 3 shows that 68% of patients have low 
levels of calcium, the main reason for this hypocalcemia is due to Vitamin 
D deficiency. It is worth mentioning that most patients have calcium levels 
less than the normal levels but close to the normal values; this because 
PTH compensates for the deficiency. For this reason, a significant negative 
correlation between PTH and calcium was observed, as shown in Fig. 4. 
On the other hand, Fig. 5 shows a significant negative correlation between 
calcium and phosphate, and thus phosphate levels increased. Therefore, 
calcium binds with phosphate and forms a calcium phosphate complex 
(CaHPO4), this is another cause of hypocalcemia among ESRD patients. 
Fig. 1: Control mean value patient mean value for calcium and 
phosphate
Fig. 2: Control mean value versus patients mean value for 
parathyroid hormone
Fig. 3: Distribution of calcium among hemodialysis patients
Fig. 4: Correlation between calcium and parathyroid hormone
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Fig. 6 shows that 70% of patients have an elevation in phosphate levels 
(hyperphosphatemia), this situation is due to the role of FGF-23, which 
reduce the expression of type II sodium/phosphate cotransporters (NaPi-
2a and NaPi-2c) and allow phosphate excretion [5], but FGFR1-Klotho 
complex is downregulated in kidneys [6]. However, this contributes to the 
resistance of the effect of FGF-23 and enhances phosphate retention. There 
is a significant positive correlation between creatinine and phosphate, as 
shown in Fig. 7, where Fig. 8 also shows a significant positive correlation 
between phosphate and PTH. This gives a further significant positive 
correlation between PTH and creatinine (Fig. 9).
It was found that among ESRD patients, there is low GFR, which leads 
to an increase in the level of creatinine, and decreased excretion of 
phosphate; thus, as a result, this causes hyperphosphatemia and 
hypersecretion of PTH by the mechanism of FGF-23. However, bone and 
mineral metabolism disorders occur in those patients, as PTH trying to 
compensate for the decline in calcium by increasing bone resorption. 
Cardiovascular diseases occur as a result due to the accumulation of 
calcium phosphate complex, leading to coronary artery calcification. 
Many other factors cause SHPT, not only kidney failure; these factors 
are not included in this study.
Our finding in this study was consistent with the other studies carried 
out in different countries [4,6]. A study by Arora et al. [6] was found 
that the mean value of calcium (7.90±1.16 mg/dL) and the mean value 
of phosphate was (6.44±1.72 mg/dL). Besides, in the same study, it 
was also found that there is a positive correlation between PTH and 
creatinine, and a negative correlation between PTH and calcium, which 
are similar to our results. Moreover, a study by Sliem et al. [4] was 
determined that the mean value of calcium was (8.2±1.05 mg/dL) and 
the mean value of phosphate was (5.94±1.7 mg/dL), which are also 
similar to our finding. Vitamin D was not included in our study because 
it is not measured regularly for all ESRD patients within the follow-up, 
Fig. 5: Correlation between phosphate and calcium
Fig. 6: Distribution of phosphate among hemodialysis patients
Fig. 7: Correlation between phosphate and creatinine
Fig. 8: Correlation between phosphate and parathyroid hormone
Fig. 9: Correlation between creatinine and parathyroid hormone
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it is only measured to some patients according to the patient situation. 
Our study has some limitations such as it is only carried out for patient’s 
reports in 2019 and one hospital.
CONCLUSION
The study showed that SHPT is common among patients with ESRD. 
The most complications of SHPT are mineral and bone metabolism 
disorders and cardiovascular diseases. Thus, early detection and 
treatment of SHPT may control these complications. Further studies 
with a large sample size and different sites are needed to confirm 
accurately the different parameter correlations.
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